Accès gratuit
Med Sci (Paris)
Volume 18, Numéro 12, Décembre 2002
Page(s) 1282 - 1286
Section M/S Revues : Articles de Synthèse
Publié en ligne 15 décembre 2002
  1. Ring CJ. Cytolytic viruses as potential anti-cancer agents. J Gen Virol 2002; 83: 491–502. [Google Scholar]
  2. Norman KL, Farassati F, Lee PW. Oncolytic viruses and cancer therapy. Cytokine Growth Factor Rev 2001; 12: 271–82. [Google Scholar]
  3. Virgin HW, Tyler KL, Dermody TS. Reovirus. In: Nathanson N, ed. Viral pathogenesis. Philadelphia: Lippincott-Raven, 1996 : 669–99. [Google Scholar]
  4. Nibert ML, Schiff LA. Reoviruses and their replication. In : Knipe DM, Howley PM, eds. Fundamental virology, 4th ed. Philadelphia: Lippincott-Raven Publishers, 2001 : 793–842. [Google Scholar]
  5. Rosen L, Evans HE, Spickard A. Reovirus infections in human volunteers. Am J Hyg 1963; 77: 29–37. [Google Scholar]
  6. Organ EL, Rubin DH. Pathogenesis of reovirus gastrointestinal and hepatobiliary disease. Curr Top Microbiol Immunol 1998; 233 : 67–83. [Google Scholar]
  7. Bisaillon M, Bernier L, Sénéchal S, Lemay G. A glycosyl hydrolase activity of mammalian reovirus σ1 protein can contribute to viral infection through a mucus layer. J Mol Biol 1999; 286: 759–73. [Google Scholar]
  8. Danis C, Lemay G. Protein synthesis in different cell lines infected with orthoreovirus serotype 3: inhibition of host-cell protein synthesis correlates with accelerated viral multiplication and cell killing. Biochem Cell Biol 1993; 71: 81–5. [Google Scholar]
  9. Hashiro G, Loh PC, Yau JT. The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 1977; 54: 307–15. [Google Scholar]
  10. Duncan MR, Stanish SM, Cox DC. Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol 1978; 28: 444–9. [Google Scholar]
  11. Strong JE, Lee PWK. The verbB oncogene enhanced cellular susceptibility to reovirus infection. J Virol 1996; 70: 612–6. [Google Scholar]
  12. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 1998; 17: 3351–62. [Google Scholar]
  13. Kaufman RJ. The double stranded RNA-activated protein kinase PKR. In : Sonenberg N, Hershey JWB, Mathews MB, eds. Translation control of gene expression. New York: Cold Spring Harbor Laboratory Press, 2000 : 503–27. [Google Scholar]
  14. Samuel CE. Reoviruses and the interferon system. Curr Top Microbiol Immunol 1998; 233 : 125–45. [Google Scholar]
  15. Schiff LA. Reovirus capsid proteins σ3 and µ1 : interactions that influence viral entry, assembly, and translational control. Curr Top Microbiol Immunol 1998; 233: 167–83. [Google Scholar]
  16. Gale M, Katze MG. Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase. Pharmacol Ther 1998; 78: 29–46. [Google Scholar]
  17. Mundschau LJ, Faller DV. Oncogenic Ras induces an inhibitor of double stranded RNA-dependent eukaryotic initiation factor 2α-kinase activation.J Biol Chem 1992; 267: 23092–8. [Google Scholar]
  18. Mundschau LJ, Faller DV. Endogenous inhibitors of the dsRNA-dependent elF-2αprotein kinase PKR in normal and ras transformed cells. Biochimie 1994; 76: 792–800. [Google Scholar]
  19. Reuter CWM, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational mechanism-based treatment for hematologic malignancies. Blood 2000; 96: 1655–69. [Google Scholar]
  20. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282: 1332–4. [Google Scholar]
  21. Wilcox ME, Yang WQ, Senger D, et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 2001; 93: 903–12. [Google Scholar]
  22. Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossakowska A, Lee PW. Oncolytic reovirus against ovarian and colon cancer. Cancer Res 2002; 62: 1696–701. [Google Scholar]
  23. Norman KL, Coffey MC, Hirasawa K, et al. Reovirus oncolysis of human breast cancer. Hum Gene Ther 2002; 13: 641–52. [Google Scholar]
  24. Alain T, Hirasawa K, Pon KJ, et al. Reovirus therapy of lymphoid malignancies. Blood 2002 (PMID 12393565). [Google Scholar]
  25. Hirasawa K, Yoon CS, Nishikawa SG, Waisman DM, Lee PWK. Reovirus therapy of metastatic cancer models in immune-competent mice. Annual Meeting of the American Association for Cancer Research 2001. Résumé: planner/ presentation, id=13225. [Google Scholar]
  26. Oberhaus SM, Dermody TS, Tyler KL. Apoptosis and the cytopathic effects of reovirus. Curr Top Microbiol Immunol 1998; 233 : 23–49. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.